Intellia Therapeutics, Inc vs. Alpha Teknova, Inc. Common Stock
Intellia Therapeutics, Inc and Alpha Teknova, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| NTLA | TKNO | |
|---|---|---|
| Market Cap | $1.61 billion | $370.99 million |
| Revenue (TTM) | — | $43.70 million |
| Net Income (TTM) | — | $-16,769,000 |
NTLA leads on 1 of 1 size & scale factors.
Valuation
| NTLA | TKNO | |
|---|---|---|
| Price / Book | — | 5.93 |
| Price / Sales | — | 8.49 |
NTLA and TKNO split the valuation factors evenly.
Profitability
| NTLA | TKNO | |
|---|---|---|
| Net Margin | — | -38.37% |
| Return on Equity | — | -26.79% |
NTLA and TKNO split the profitability factors evenly.
Risk & Sentiment
| NTLA | TKNO | |
|---|---|---|
| Short Interest | 2.43% | 0.07% |
TKNO leads on 1 of 1 risk & sentiment factors.
Dig deeper: NTLA overview, NTLA financials, TKNO overview, TKNO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.